GleamWall
中文EN

JNJ JOHNSON & JOHNSON

Pharmaceutical Preparations · NYSE · SEC CIK 200406 · Fiscal year ends 01/03

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.8%
TTM net income YoY-35.9%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR5.9%
Net income 3-yr CAGR-22.5%

Margins

Gross margin67.6%
Operating margin—
Net margin16.2%
FCF margin20.7%
EBITDA margin—

Returns

ROE20.0%
ROA8.2%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets58.7%
Debt / equity0.55x
Current ratio1.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.63x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-28FY20242024-12-29FY20232023-12-31FY20222023-01-01FY20212022-01-02
Income statement
Revenue$94.19B$88.82B$85.16B$79.99B$78.74B
Cost of revenue$30.26B$27.47B$26.55B$24.60B$23.40B
Gross profit$63.94B$61.35B$58.61B$55.39B$55.34B
R&D expense$109.00M$1.84B$483.00M$0$0
SG&A expense$23.68B$22.87B$21.51B$20.25B$20.12B
Interest expense$971.00M$755.00M$772.00M$276.00M$183.00M
Pretax income$32.58B$16.69B$15.06B$19.36B$19.18B
Income tax$5.78B$2.62B$1.74B$2.99B$1.38B
Net income$26.80B$14.07B$35.15B$17.94B$20.88B
EPS (basic)11.135.8413.886.837.93
EPS (diluted)11.035.7913.726.737.81
Dividends declared per share5.144.914.704.454.19
Weighted avg. shares (diluted)2.43B2.43B2.56B2.66B2.67B
Balance sheet
Cash & equivalents$19.71B$24.11B$21.86B$14.13B$14.49B
Short-term investments$393.00M$417.00M$1.07B$9.39B$17.12B
Receivables$17.18B$14.84B$14.87B$14.04B$15.28B
Inventory$14.19B$12.44B$11.18B$10.27B$10.39B
Current assets$55.62B$55.89B$53.49B$55.29B$60.98B
PP&E, net$23.17B$20.52B$19.90B$17.98B$18.96B
Goodwill$48.77B$44.20B$36.56B$36.05B$25.44B
Intangibles$50.40B$37.62B$34.17B$38.49B$46.39B
Total assets$199.21B$180.10B$167.56B$187.38B$182.02B
Current liabilities$54.13B$50.32B$46.28B$55.80B$45.23B
Short-term debt$8.49B$6.00B$3.50B$12.80B$3.80B
Long-term debt$39.44B$30.65B$25.88B$26.89B$29.98B
Total debt$47.93B$36.65B$29.38B$39.69B$33.78B
Total liabilities$117.67B$108.61B$98.78B$110.57B$108.00B
Shareholders' equity$81.54B$71.49B$68.77B$76.80B$74.02B
Net debt$28.22B$12.55B$7.52B$25.56B$19.30B
Cash flow statement
Operating cash flow$24.53B$24.27B$22.79B$21.19B$23.41B
Capital expenditure$4.83B$4.42B$4.54B$4.01B$3.65B
Free cash flow$19.70B$19.84B$18.25B$17.18B$19.76B
Investing cash flow-$23.59B-$18.60B$878.00M-$12.37B-$8.68B
Financing cash flow-$5.54B-$3.13B-$15.82B-$8.87B-$14.05B
Depreciation & amortization$7.50B$7.34B$7.49B$6.97B$7.39B
Stock-based compensation$1.35B$1.18B$1.16B$1.14B$1.14B
Share buybacks$5.95B$2.43B$5.05B$6.04B$3.46B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.